MRI/Ultrasound Fusion Guided Prostate Cryotherapy
Part of paid clinical trials in Miami Lakes, Florida.
- Sponsor
- Urological Research Network, LLC
- Study ID
- NCT02381990
- Status
- Recruiting
Conditions
- Cancer of the Prostate
- Neoplasms Prostate
Eligibility Criteria
- Sex
- MALE
- Age
- 55 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- FUSE IMAGE MRI GUIDED PROSTATE CRYOTHERAPY — PROCEDUREBiopsy proven Prostate Cancer is delimited and defined by MP-MRI. The MRI study is fused with transrectal ultrasound in realtime. The cryogenic "cryoprobes/devices" are employed to freeze and all "circuled or noted" cancer lesions. Two freeze 8 min/ thaw 10 min clycles are performed. Thermocouples are used to monitor treatment areas and safety margins
Study Details
Registration of Prostate Cancer patients undergoing Prostate Cryotherapy guided by Mutiparametric-MRI (MP-MRI) highlighting biopsy confirmed regions. The primary outcome measure is 5 year oncological control. Secondary aim is lack of progression beyond the prostate gland. The aim of intervention is to eradicate prostate cancer disease in the treated area while imposing no or minimal deleterious effects in quality of life.
Key Dates
- Start date
- Aug 31, 2013
- Status verified
- Jan 2023
- Primary completion
- Aug 31, 2023
- Completion
- Aug 31, 2033
Study Design
- Enrollment
- 5,000 participants (estimated)
Primary Outcome Measure
Oncological Control [ Time Frame: 1 Year ]
Central Contacts
- CIELO D GUERRA, BS305-515-9887
- LUANDA SIANO, PA305-822-7227
Locations (1)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| Urological Research Network | Miami Lakes | Florida | 33016 | FERNANDO J BIANCO, MD (PRINCIPAL_INVESTIGATOR) EDWARD L GHEILER, MD (SUB_INVESTIGATOR) ARIEL M KAUFMAN, MD (SUB_INVESTIGATOR) EUSEBIO J LUNA, MD (SUB_INVESTIGATOR) |
Find similar trials in Miami Lakes, FL
By research site
Related Studies
- MRI/Ultrasound Fusion Guided Laser Ablation of Prostate CancerRecruiting · Urological Research Network, LLC · Miami Lakes, Florida
- This Study Will Explore Whether a Combination of the Investigational Drug Mevrometostat (PF-06821497) and Enzalutamide Will Work Better Than Taking Enzalutamide Alone in Participants With mCSPC Who Are ARPI naïve.PHASE3 · Recruiting · Pfizer · Huntsville, Alabama
- Investigation of Impact of AI on Prostate Cancer WorkflowRecruiting · Case Comprehensive Cancer Center · Cleveland, Ohio
- Impact of an Electronic Health Record Maintenance Alert on PSA Screening Rates in a 10-Hospital Integrated Health SystemRecruiting · Washington University School of Medicine · St Louis, Missouri